Want to see YARW full AI Analyst Report?
YARW Stock Chart & Stats
$28.05
$2.95(10.52%)
At close: 4:00 PM EDT
$28.05
$2.95(10.52%)
Day’s Range― - ―
52-Week Range$14.00 - $74.45
Previous CloseN/A
Volume13.75K
Average Volume (3M)2.75M
Market Cap
$24.12M
Enterprise Value$0.63
Total Cash (Recent Filing)$24.93M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.79%
Share Statistics
EPS (TTM)-0.48
Shares Outstanding859,790
10 Day Avg. Volume3,707,448
30 Day Avg. Volume2,746,500
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.89
Price to Sales (P/S)43.53
P/FCF Ratio-0.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-29.5
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetEffectively no debt materially reduces refinancing and interest-rate risk for this clinical-stage biotech. Low leverage gives management structural financial flexibility to prioritize R&D and trials without immediate interest burdens, improving solvency resilience over the next 2–6 months.
Substantial Pre-closing FinancingThe roughly $200M private financings tied to the merger materially extend operating runway and lower near-term financing pressure. This structural capital infusion funds Phase 2 development and operations, providing optionality for partnerships and reducing immediate dilution risk in the medium term.
Clinical Progress & FDA Fast TrackFDA Fast Track status plus Phase 2a/2b dosing are durable de-risking milestones: regulatory prioritization can accelerate development dialogue and trial timelines, while Phase 2 readouts will materially change program value. Partnered China development adds geographic development capacity.
Bears Say
Tiny And Declining RevenueRevenue near zero and a recent 20% decline mean the company lacks a commercial revenue base. Structurally reliant on external capital, the business cannot self-fund R&D or scaling, increasing likelihood of future financing and constraining strategic flexibility over the coming months.
Persistent Cash Burn And Negative FCFConsistent negative operating and free cash flow at meaningful absolute levels versus revenue creates an ongoing funding dependence. Even with recent financing, continued cash burn makes additional capital raises likely, raising dilution and execution risk if market conditions change.
Large Operating Losses And Negative MarginsDeep negative margins and sizable net losses show the operating model is far from profitable. Until clinical assets are partnered, approved, or commercialized, entrenched losses and negative returns to shareholders will persist, limiting capital efficiency and long-term return prospects.
Yarrow Bioscience News
YARW FAQ
What was Yarrow Bioscience’s price range in the past 12 months?
Yarrow Bioscience lowest stock price was $14.00 and its highest was $74.45 in the past 12 months.
What is Yarrow Bioscience’s market cap?
Yarrow Bioscience’s market cap is $24.12M.
When is Yarrow Bioscience’s upcoming earnings report date?
Yarrow Bioscience’s upcoming earnings report date is Aug 19, 2026 which is in 21 days.
How were Yarrow Bioscience’s earnings last quarter?
Yarrow Bioscience released its earnings results on May 07, 2026. The company reported -$0.084 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.084.
Is Yarrow Bioscience overvalued?
According to Wall Street analysts Yarrow Bioscience’s price is currently Overvalued.
Does Yarrow Bioscience pay dividends?
Yarrow Bioscience pays a Notavailable dividend of $0.402 which represents an annual dividend yield of 0.79%. See more information on Yarrow Bioscience dividends here
What is Yarrow Bioscience’s EPS estimate?
Yarrow Bioscience’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Yarrow Bioscience have?
Yarrow Bioscience has 859,790 shares outstanding.
What happened to Yarrow Bioscience’s price movement after its last earnings report?
Yarrow Bioscience reported an EPS of -$0.084 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.582%.
Which hedge fund is a major shareholder of Yarrow Bioscience?
Currently, no hedge funds are holding shares in YARW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Yarrow Bioscience
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
YARW Stock 12 Month Forecast
Average Price Target
―Ownership Overview
2.97% Insiders
1.77% Mutual Funds
― Other Institutional Investors
94.64% Public Companies and
Individual Investors